Myelofibrosis
The latest news, research, and perspectives in myelofibrosis (MF). A primary subtype of myeloproliferative neoplasms (MPNs), this rare blood cancer scars the bone marrow so that it cannot properly produce blood cells.
Advertisement
Researchers also observed potential disease modification via rapid stabilization of platelets and stable hemoglobin levels.
There were no significant differences in response rates with pegylated interferon-alpha versus hydroxyurea in MPN treatment.
The trial is based on “compelling data” from arm III of the ongoing phase II MANIFEST study.
82.5% of MF patients experienced rapid significant decreases in palpable spleen size after two months of ruxolitinib therapy.
The median duration of therapy is around three years in patients with intermediate or high-risk MF.
The analysis included 346 patients with CALR-mutated MF who were transplanted in 123 centers between 2005 and 2019.
Advertisement
Myelofibrosis Awareness Day is marked on September 20th each year.
Researchers presented updated data from the phase I XPORT-MF-034 trial at the Eleventh SOHO Annual Meeting.
The open-label ACE-536-MF-001 study included patient cohorts grouped by transfusion dependance and ruxolitinib therapy.
In PERSIST-2, treatment with pacritinib demonstrated a significant SVR benefit compared with the best available therapy, incl
Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease.
Ruxolitinib, an oral JAK1/JAK2 inhibitor, initially received FDA approval in 2011.
Researchers conducted the study because the mechanism by which pacritinib improves anemia has not been elucidated.
Researchers conducted an indirect comparison analysis of multiple clinical trials to address the question.
In June 2023, the manufacturer of the drug initiated XPORT-MF-034, a pivotal phase III clinical trial.
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
At a median follow-up of 55 weeks, 90% of patients completed 24 weeks of treatment and 56% completed 48 weeks of treatment.
Initiation of ruxolitinib therapy within two years of diagnosis was associated with increased response rates in all patients.
Just under half (43%) of patients receiving ruxolitinib achieved a CR, while 26% achieved a CR on the best available therapy.
However, achieving a spleen volume reduction on the best available therapy was not linked with improved survival.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.